LEWES, Del., Nov. 7, 2025 /PRNewswire/ — HiBy has officially launched its new flagship portable HiFi player, RS8 II, on October 30, 2025. The RS8 II integrates HiBy’s advanced technologies in portable audio with deep insights into market trends, redefining high-end portable music players. It features a high-performance processor, upgraded audio architecture, and multiple connectivity options, supporting high-resolution audio formats and versatile output, providing users with a complete digital audio experience and flexible connectivity.

“HIBY RS8 II : the Evolution of RS Series”

The player is powered by the Qualcomm Dragonwing QCS8550 (8Gen2 platform) and the upgraded third-generation DARWIN audio architecture, paired with AdaptiveAMP, offering dynamic A/B-class amplification with 64-level adjustability and THD+N as low as 0.0008%. Its powerful CPU+GPU+NPU+FPGA+DSP array combined with a precisely matched R2R resistor network ensures accurate high-resolution audio reproduction. Sankofa AI tonality simulation allows users to enjoy sound signatures modeled after classic audio sources such as MD, CD, cassette, and reel-to-reel tape players, with free updates for a personalized HiFi experience.

In terms of design, the RS8 II adopts a unibody aluminum chassis with a glass back, geometric lines, and three-dimensional cuts for a distinctive appearance. The rear panel is engraved with RS and “DESIGNED BY HIBY,” hexagonal side buttons symbolize the Darwin architecture, and the multi-faceted rotary knob reflects light like a diamond. At 425g, the player balances flagship-level performance with portability.

The RS8 II features a 5.5-inch 1080×1920 HD display and a 46.8Wh battery supporting up to 80W PD3.0 fast charging. Wireless connectivity includes Wi-Fi 7 MIMO and Bluetooth 5.3 (compatible with AptX Adaptive & AptX Lossless). Audio performance is enhanced by 45.1584MHz and 49.152MHz NDK femtosecond oscillators, supporting DSD1024, PCM 1536kHz/32bit, and MQA 16X, and Direct Transport Audio (D.T.A.), which bypasses Android system SRC for high-resolution playback from third-party apps. Output options include 3.5mm PO/LO combo, 4.4mm BAL Phone-out, 4.4mm BAL Line-out, Type-C digital audio supporting SPDIF coaxial, USB Audio In/Out, and the first-time portable player I²S interface, greatly expanding connectivity possibilities.

With its advanced tonality simulation, ultra-low distortion, and efficient power management, the RS8 II delivers an unprecedented high-fidelity listening experience, establishing a new benchmark for portable HiFi.

About HiBy

Founded in 2011, HiBy is a leading authority in portable audio, specializing in the development, design, and sales of top-tier portable audio products through its subsidiaries HiBy Music and HiBy Digital.

Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery

SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ — Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced the presentation of three studies at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place November 5-9 in Maryland, U.S. The findings highlight how Lunit’s AI-powered digital pathology technologies—Lunit SCOPE IO® and Lunit SCOPE® uIHC—can advance precision oncology by uncovering predictive immune signatures and guiding antibody-based drug development.

Lunit and CellCarta presented a comparative analysis demonstrating that AI can standardize tumor immune phenotyping across multiple cancer types, including non-small cell lung, colorectal, and urothelial cancers. When assessing tumor and stromal segmentation, Lunit SCOPE IO showed high concordance with pathologist assessments based on traditional immunohistochemistry (Spearman’s correlation coefficients of 0.91 and 0.86). Threshold calibration improved alignment between the AI-based and pathologist scoring of inflamed, excluded, and desert immune phenotypes and improved its reliability and reproducibility. These results position Lunit SCOPE IO as a scalable solution for immune profiling, reducing reliance on additional IHC staining and enabling consistent analysis of the tumor immune microenvironment in both research and clinical practice.

Lunit also introduced new data showcasing the utility of Lunit SCOPE uIHC, the company’s AI-powered quantitative IHC platform, in mapping spatial interactions between tumor-infiltrating lymphocytes (TILs) and 74 membrane-specific protein targets currently in development for antibody-based therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs). Analyzing over 47,000 IHC images across 34 cancer types, the study revealed that while most protein targets showed decreased TIL density within expression regions, select proteins such as PD-L1 and TNFRSF4, displayed positive spatial correlation with lymphocyte infiltration. Notably, FGFR4 expression was linked to increased intra-tumoral lymphocytes in colorectal, non-squamous lung, and uterine cancers, suggesting its potential as a BiTE target. The findings demonstrate how Lunit SCOPE uIHC can integrate spatial immune context into early drug discovery workflows, accelerating the identification and validation of therapeutic targets.

In another research, Lunit presented new data confirming the predictive power of AI-based spatial profiling in MET-mutated non-small cell lung cancer (NSCLC), demonstrating how AI-powered image-based profiling can uncover immunologically active subtypes within cancers.

“At SITC 2025, we’re showcasing how our digital pathology AI, the Lunit SCOPE suite, can bridge research and real-world clinical practice,” said Brandon Suh, CEO of Lunit. “From identifying immunotherapy-responsive subtypes to guiding antibody-based drug discovery, our AI technology is redefining how we understand and target the tumor–immune interface. Collaborations like ours with CellCarta are key to unlocking the full potential of this transformation.”

Lunit’s featured studies at SITC 2025 include:

• Poster Presentation [#1347]: AI-powered image-based spatial profiling of MET-mutated non-small cell lung cancer identifies immune-active MET exon 14 skipping subtypes as potential immunotherapy targets, Zachary Wallen, Labcorp Oncology
• Poster Presentation [#1264]: Artificial Intelligence-Powered Spatial Analysis of Tumor Microenvironment Identifies Immune Phenotypes in H&E Stained Non-Small Cell Lung Cancer, Colorectal Cancer and Urothelial Cancer, Elizabeth Ross, CellCarta
• Poster Presentation [#1098]: Unveiling spatial correlation between cell surface targets and lymphocytes via artificial intelligence (AI)-powered quantitative immunohistochemistry (IHC) analysis, Sukjun Kim, Lunit

Visit Lunit at booth #818 to learn more about the company’s latest innovations in AI-powered digital pathology and oncology research.

About Lunit

Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.

Following the integration of Volpara, Lunit now offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while Lunit SCOPE platform is used in research partnership with global pharma leaders for biomarker development and companion diagnostics.

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io/en.

VICTORIA, Seychelles, Nov. 7, 2025 /PRNewswire/ — Bitget, the world’s largest Universal Exchange (UEX), today announced a limited-time 90% reduction in stock futures trading fees, marking one of the most aggressive pricing initiatives ever launched by a major digital asset platform.

The promotion arrives as U.S. equity markets surge on the back of the AI-driven bull run, creating what Bitget describes as a “rare window of volatility and opportunity” for traders worldwide. Under the campaign, all stock futures trading pairs on Bitget will feature ultra-low fees of just 0.0065%, making it significantly cheaper than comparable offerings on traditional CFD platforms.

The announcement follows record activity on Bitget’s platform, where the stock-futures segment recently exceeded $300 million in single-day trading volume, highlighting the rapid adoption of tokenized-equity products and institutional-grade derivatives among global users.

“This earnings season is one of the most dynamic in years,” said Gracy Chen, CEO of Bitget. “With technology stocks leading global momentum, we want our users to seize these opportunities with institutional-grade efficiency and minimum cost barriers. This 90% fee reduction puts professional-level access into the hands of every trader.”

The campaign reflects Bitget’s long-term commitment to its Universal Exchange (UEX) vision — creating a unified platform where users can seamlessly access both crypto-native and traditional financial products under one account. By bridging tokenized assets and traditional markets, Bitget continues to make global investing more transparent, accessible, and cost-efficient.

This initiative also reinforces Bitget’s positioning as one of the few exchanges that successfully integrates crypto futures, tokenized equities, and AI-driven trading tools into a single ecosystem. With ultra-competitive fees, Bitget aims to attract both retail and institutional users seeking diversified exposure during a pivotal market cycle.

“Our mission is simple — make global financial participation frictionless,” added Gracy Chen, CEO of Bitget. “By bringing stock futures, crypto markets, and advanced AI tools into one platform, Bitget is helping traders navigate the Universal Exchange era with speed, data, and confidence.”

The 90% fee reduction is available for a limited time and coincides with the peak of the earnings season, when trading volumes and volatility traditionally spike. Bitget expects the campaign to further accelerate adoption of its stock futures products and onboard a new generation of multi-asset traders.

About Bitget

Established in 2018, Bitget is the world’s leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Bitget Wallet is a leading non-custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi-chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built into a single platform.

Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World’s Top Football League, LALIGA, in EASTERN, SEA and LATAM markets. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP™, one of the world’s most thrilling championships.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

Late-breaking poster presentations show HCB101’s favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy

TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the presentation of two late-breaking abstracts on its lead asset, HCB101, at the 40^th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 5-9, 2025, in National Harbor, Maryland. Both datasets were accepted for late-breaking poster presentations, highlighting the program’s potential impact on innate immune checkpoint blockade.

HCB101’s progress reflects its distinct engineering compared to earlier CD47-targeting approaches. First-generation CD47 antibodies, such as magrolimab and lemzoparlimab, demonstrated clinical activity but faced significant safety or efficacy challenges, leading to discontinuations or halted collaborations. Second-generation wild-type SIRPα fusions, such as maplirpacept (TTI-622), improved safety but did not deliver sufficient efficacy in solid tumors, limiting their adoption. IgG1-based fusions attempted to boost immune activation but triggered excessive Fcγ-mediated toxicity and poor tolerability, restricting their use mainly to hematologic malignancies. Third-generation engineered SIRPα fusions with inactivated IgG1 Fc improved safety in combinations but showed limited standalone efficacy. 

“The acceptance of two late-breaking abstracts at SITC for HCB101 monotherapy and combination therapy, along with our earlier preclinical abstract for HCB301, a tri-specific fusion targeting SIRPα/CD47, PD-1/PD-L1, and TGFβ, reinforces the scientific breadth of our platform across innate and adaptive immunity,” said Scott Liu, Ph.D., Founder, Chairman, and CEO of HanchorBio. “HCB101 was purposely engineered to overcome the cytopenias seen with first-generation anti-CD47 antibodies while maintaining potent immune activation. In second-line gastric cancer, the combination of HCB101 with standard-of-care therapy achieved a 100% confirmed response rate in the active-dose cohort, far exceeding the 28% ORR benchmark from the RAINBOW trial. These results position HCB101 not just as a safer SIRPα-CD47 backbone, but as a next-generation macrophage checkpoint immunotherapy with best-in-class potential.”

Late-Breaking Abstract Highlights (Data as of August 2025)

1. HCB101-101 Monotherapy Study (NCT05892718)

Title: HCB101, a Next-Generation Fc-Engineered SIRPα-CD47 Fusion Protein, Demonstrates Favorable Safety and Early Antitumor Activity in Advanced Cancers

• In the ongoing Phase 1a dose-escalation, no dose-limiting toxicities (DLTs) have been observed at doses up to 24 mg/kg.
• CD47 receptor occupancy ≥99% achieved at doses ≥5 mg/kg, with dose-proportional pharmacokinetics.
• Confirmed partial responses seen in head and neck squamous cell carcinoma (HNSCC) and marginal zone lymphoma (MZL).
• Several patients achieved stable disease, with progression-free survival up to 32 weeks.

2. HCB101-201 Combination Therapy Study (NCT06771622)

Title: Phase 1b/2a Study of HCB101 Combined with Standard Therapies Demonstrates Manageable Safety and Dose-Dependent Antitumor Activity in Immunologically Cold Advanced Solid Tumors

• In second-line gastric cancer (GC):
  • 100% confirmed partial response rate (6/6 evaluable patients) at active doses when combined with ramucirumab and paclitaxel.
  • Tumor shrinkage up to 78%, surpassing the ~26.5% ORR benchmark from RAINBOW.
• In first-line triple-negative breast cancer (TNBC):
  • Confirmed partial response with 73% tumor reduction at the effective dose.
• Safety was manageable and consistent with the cytopenia-sparing design, with only minimal hematologic effects observed.

Dr. Fangling Ning, Investigator from the Affiliated Hospital of Binzhou Medical University, commented, “What’s unique about HCB101 is that it avoids the cytopenias that plagued anti-CD47 antibodies by minimizing red blood cell binding, while still engaging CD47 strongly on tumor cells. In our gastric cancer cohort, the responses at active doses are encouraging in a patient population that historically has had limited options. These findings validate HCB101’s unique design and suggest meaningful potential in immunologically cold tumors.”

About HCB101: A Differentiated CD47-SIRPα Blockade

HCB101 is a 3.5^th-generation, affinity-optimized SIRPα-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio’s proprietary FBDB™ platform. It is engineered for selective CD47 targeting with low red blood cell (RBC) binding, thereby avoiding the anemia and thrombocytopenia commonly associated with earlier anti-CD47 monoclonal antibodies, while preserving strong antibody-dependent cellular phagocytosis (ADCP) and innate-to-adaptive immune bridging. Key differentiators of HCB101:

• Enhanced safety: Cytopenia-sparing profile, with no DLTs observed up to 30 mg/kg and receptor occupancy >90% at ≥1.28 mg/kg, supporting a broad therapeutic window.
• Robust immune activation: Engineered to enhance ADCP and bridge innate-to-adaptive immunity, with evidence of durable immune-mediated tumor control in monotherapy.
• Broad tumor applicability: Demonstrated activity across >80 PDX and CDX preclinical models, with early clinical signals in gastric cancer, TNBC, HNSCC, non-Hodgkin lymphoma, and ovarian cancer.
• Clinical translation: Shows durable disease control as monotherapy and a 100% confirmed partial response rate (6/6) in 2L gastric cancer when combined with ramucirumab and paclitaxel, with additional confirmed responses in 1L TNBC and 2L HNSCC, substantially exceeding historical benchmarks.

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global biotechnology company specializing in immuno-oncology. It is led by an experienced team of pharmaceutical industry veterans with a proven track record in biologics discovery and international development, aiming to rewrite the landscape of cancer therapies. Committed to reactivating the immune system to fight diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables the development of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By advancing breakthroughs in multi-functional, innovative molecular configurations in R&D and improving CMC manufacturing processes, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit: https://www.hanchorbio.com

Head of Al Nao Hospital in Sudan recognized for sustaining critical medical care amid civil war
and saving hundreds of lives

NEW YORK, Nov. 7, 2025 /PRNewswire/ — The Aurora Humanitarian Initiative announced Thursday evening that Dr. Jamal Eltaeb has been named the 2025 Aurora Prize Laureate. The $1 million Aurora Prize for Awakening Humanity honors individuals who risk their lives to save others. This year, Aurora recognizes Dr. Eltaeb’s extraordinary courage and steadfast dedication to providing care for those trapped in conflict.

Dr. Jamal Eltaeb. Photo by Luke Dray

Amid Sudan’s devastating civil war and the near-total collapse of the country’s health system, Dr. Eltaeb has kept Al Nao Hospital in Omdurman operating as one of the last functioning referral hospitals in greater Khartoum—a testament to his resilience and leadership under fire.

“Growing up, I saw how fragile life can be and how much difference one person’s care and knowledge can make. I wanted to be a doctor because I wanted to serve people in their most vulnerable moments,” Dr. Eltaeb said. “The Aurora Prize encourages doctors, teachers, humanitarians, and ordinary people everywhere to keep going, knowing that their effort matters. It is a reminder that one person’s courage can inspire change and that compassion has the power to heal. Even the smallest act of kindness can bring hope.”

“At a time when indifference is spreading and compassion under siege, Dr. Eltaeb stands as living proof that humanity is not lost,” said Noubar Afeyan, Co-Founder and Chair of the Board of Directors of the Aurora Humanitarian Initiative and Founder and CEO of Flagship Pioneering. “In a world where the ‘inhumanitarians’ too often dominate the headlines, Dr. Eltaeb reminds us that the humanitarian spirit endures—and that each of us has a responsibility to keep it alive.”

The 2025 Laureate was announced at the Aurora Prize Ceremony held on Ellis Island, a symbol of refuge and renewal, marking ten years of Aurora’s global effort to highlight grassroots humanitarians.

Dr. Eltaeb was selected through a process that considered more than 800 nominations. As the 2025 Aurora Prize Laureate, he will receive a $1 million award to expand his work and also support other local leaders and grassroots organizations assisting communities in need.

“In the face of unimaginable danger and deprivation, Dr. Eltaeb has shown what true humanitarian leadership looks like,” said Lord Ara Darzi, Chair of the Aurora Prize Selection Committee and Co-Director of the Institute of Global Health Innovation at Imperial College London. “Aurora is honored to support his mission and to spotlight the resilience of those enduring conflict. Dr. Eltaeb’s selflessness reminds us that even amid war, humanity can prevail.”

Since the conflict escalated in Sudan in April 2023, Dr. Eltaeb has navigated repeated bombardments, collapsing infrastructure, and the acute shortages of electricity and medical supplies, including anesthesia, ensuring that hundreds of wounded, displaced and critically ill patients continue to receive care. Under his leadership, Al Nao Hospital has become a lifeline for the community, embodying resilience, solidarity, and unwavering dedication to saving lives under the most challenging conditions.

“Dr. Eltaeb embodies the principle of refusing indifference,” said Chelsea Clinton, Aurora Prize Selection Committee member and Vice Chair of the Clinton Foundation and Clinton Health Access Initiative. “His commitment to humanity lies not only in saving lives but in sustaining a community’s critical thread of dignity and care during one of Sudan’s most devastating conflicts.”

The Ceremony also recognized outstanding 2025 Aurora Humanitarians, Sally Becker, Dr. Zouhair Lahna, and Dr. Jill Seaman, and honored philanthropists who exemplify the Aurora’s core value of ‘Gratitude in Action:’ Henrietta H. Fore, Graça Machel, Michael Milken, and David Rubenstein. 

Celebrating a decade of impact in 2025, the Aurora Prize of Awakening Humanity is a flagship program of the Aurora Humanitarian Initiative, founded on behalf of the survivors of the Armenian Genocide and in gratitude to their saviors. Aurora amplifies the voices of those on the front lines of humanity’s crises and provides the resources to help them scale their impact through Gratitude in Action. Rooted in the belief that there is a human in every humanitarian and a humanitarian in every human, Aurora inspires people worldwide to act with courage and kindness.

About the Aurora Humanitarian Initiative 

The Aurora Humanitarian Initiative catalyzes lifesaving work by celebrating and supporting exceptional humanitarians around the world. Aurora was founded on behalf of the survivors of the Armenian Genocide and in gratitude to their saviors. Over the past decade, the organization has built a global network and supported more than 3.5 million people affected by humanitarian crises. By funding humanitarians around the world who continue the cycle of giving, this work contributes to proliferating humanitarianism into the future. For more information, please visit www.AuroraHumanitarian.org. 

2025 Aurora Prize Ceremony on Ellis Island, New York, November 6, 2025 © Victor Boyko/Getty Images for Aurora

NEW YORK, Nov. 7, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on November 7th

• Equities are lower Friday morning after the major indices retreated Thursday in a volatile session. The S&P 500 shed 1.1% as signs of a cooling jobs market pushed down tech stocks and cryptocurrency.
• Traders scooped up bonds amid bets that the Federal Reserve will cut interest rates due to a softening labor market. The Central Bank has one final meeting scheduled this year in Mid-December.
• NYSE IPO’s Evommune and Grupo Aeromexico popped on their first day of trading yesterday. Evommune rallied 26% in its debut while Aeromexico rose 7.1%.

Opening Bell
PENCIL celebrates its 30^th anniversary

Closing Bell
World Leaders in Data and AI (WLDA) celebrates the 2025 WLDA Summit

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2817101/NYSE_Nov_7_Market_Update.mp4 

GUIYANG, China, Nov. 7, 2025 /PRNewswire/ — The International Conference of Mountain Tourism and Outdoor Sports (MTOS) 2025 is scheduled to open on November 11 in Guiyang City, Guizhou Province, China. With the continued theme “Integration of Culture, Tourism and Sports Presents a High-Quality Life,” the Conference will feature a series of events including the International Mountain Tourism Alliance (IMTA) Annual Conference, the International Mountain Tourism Promotion Conference, a Field Trip to Guizhou Mountain Tourism Destinations, and the Bank of Guizhou – Mountain Culture, Tourism and Outdoor Sport Equipment Exhibition.

The Conference is hosted by IMTA and supported by the Department of Culture and Tourism of Guizhou Province, Sport Administration of Guizhou Province, the Foreign Affairs Office of Guizhou Province, the Guiyang Municipal People’s Government, the Guizhou Tourism Industry Development Group Co., Ltd., and the Guizhou International Cultural Science and Technological Exchange Center. Bank of Guizhou serves as the sponsor of the Conference.

As one of the main events, the IMTA Annual Conference 2025 is a key exchange and cooperation platform for mountain tourism sector. During the Conference, the “IMTA 2025 Work Summary and 2026 Priorities” will be presented, the special publication of Innovation in Mountain Tourism and Community Co-development will be released, and designations for the second group of “World Famous Tourism Mountains” and “International Mountain Hiking Tourism Demonstration Routes” will be announced. In addition, certificates will be issued to new IMTA members.

The International Mountain Tourism Promotion Conference 2025, themed “Promote Mountain Prosperity and Create Shared Brilliance,” will bring together representatives from tourism authorities of various countries, embassies and consulates in China, mountain tourism destination management organizations, and tourism-related enterprises. Insights on mountain tourism destination development will be shared, experiences in building “World-class Mountain Tourism Destinations” will be exchanged, and achievements in sustainable mountain tourism will be showcased. The Research Report on Strategies for Developing Guizhou’s Inbound Tourism Market Targeting Key Countries in the Asia-Pacific Region will also be released during the session.

Titled exclusively by Bank of Guizhou, the “Bank of Guizhou – Mountain Culture, Tourism and Outdoor Sport Equipment Exhibition” will present photographic works themed “Life Amid the Earth’s Folds”, along with distinctive cultural tourism products and innovative outdoor sports equipment. The Exhibition is intended to to highlight the diverse appeal of mountain tourism, embody the concept of “High-quality Life,” and enhance the multidimensional experience for attendees.